Differential effects of TAK-442, a novel orally active direct factor Xa inhibitor, and ximelagatran, a thrombin inhibitor, on factor V-mediated feedback on coagulation cascade and bleeding

Thrombosis and Haemostasis

Volumn 104, Issue 3, 2010, Pages 504-513

  Konishi, Noriko ^a   Hiroe, Katsuhiko ^a   Kawamura, Masaki ^b  

^a TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

^b TAKEDA PHARMACEUTICALS   (United States)

Author keywords

Anticoagulants; Blood coagulation; Haemostasis; Thrombosis

Indexed keywords

BLOOD CLOTTING FACTOR 10A INHIBITOR; BLOOD CLOTTING FACTOR 5; MELAGATRAN; TAK 442; THROMBIN; THROMBOPLASTIN; UNCLASSIFIED DRUG; XIMELAGATRAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICOAGULATION; ARTICLE; BLEEDING; BLEEDING TIME; BLOOD CLOTTING; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENCY; IN VITRO STUDY; MALE; NONHUMAN; POSITIVE FEEDBACK; PRIORITY JOURNAL; PROTHROMBIN TIME; RAT; THROMBOGENESIS; VEIN THROMBOSIS;

ADMINISTRATION, ORAL; ANIMALS; ANTICOAGULANTS; ANTITHROMBINS; AZETIDINES; BENZYLAMINES; BLOOD COAGULATION; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FACTOR V; FACTOR XA; FEEDBACK, PHYSIOLOGICAL; HEMORRHAGE; HUMANS; MALE; PHOSPHOLIPIDS; PROTHROMBIN TIME; PYRIMIDINONES; RATS; RATS, SPRAGUE-DAWLEY; RISK ASSESSMENT; SULFONES; THROMBIN; THROMBOPLASTIN; VENOUS THROMBOSIS;

EID: 77956640230     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH09-12-0817     Document Type: Article

References (35)

1. Hirsh J, Dalen J, Anderson DR, et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 2001; 119: 8S-21S.
2. Francis CW, Berkowitz SD, Comp PC, et al. EXULT A Study Group. Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement. N Engl J Med 2003; 349: 1703-1712.
3. Schulman S, Wahlander K, Lundstrom T, et al. THRIVE III Investigators. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. N Engl J Med 2003; 349: 1713-1721. (Pubitemid 37315008)
4. Olsson SB. Executive Steering Committee on behalf of the SPORTIF III Investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III). Lancet 2003; 362: 1691-1698.
5. Albers GW, Diener HC, Frison L, et al. SPORTIF Executive Steering Committee for the SPORTIF V Investigators. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. J Am Med Assoc 2005; 293: 690-698.
6. Fiessinger JN, Huisman MV, Davidson BL, et al. THRIVE Treatment Study Investigators. Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial. J Am Med Assoc 2005; 293: 681-689.
7. Colwell CW Jr, Berkowitz SD, Lieberman JR, et al. EXULT B Study Group. Oral direct thrombin inhibitor ximelagatran compared with warfarin for the prevention of venous thromboembolism after total knee arthroplasty. J Bone Joint Surg Am 2005; 87: 2169-2177.
8. Boos CJ, Lip GY. Ximelagatran: an eulogy. Thromb Res 2006; 118: 301-304.
9. Eriksson BI, Dahl OE, Rosencher N, et al. RE-MODEL Study Group. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 2007; 5: 2178-2185.
10. Hara T, Yokoyama A, Tanabe K, et al. DX-9065a, an orally active, specific inhibitor of factor Xa, inhibits thrombosis without affecting bleeding time in rats. Thromb Haemost 1995; 74: 635-639.
11. Morishima Y, Tanabe K, Terada Y, et al. Antithrombotic and hemorrhagic effects of DX-9065a, a direct and selective factor Xa inhibitor: comparison with a direct thrombin inhibitor and antithrombin III-dependent anticoagulants. Thromb Haemost 1997; 78: 1366-1371. (Pubitemid 27491312)
12. Sato K, Kaku S, Hirayama F, et al. Antithrombotic effect of YM-75466 is separated from its effect on bleeding time and coagulation time. Eur J Pharmacol 1998; 352: 59-63.
13. Wong PC, Crain EJ, Watson CA, et al. Nonpeptide factor Xa inhibitors III: effects of DPC423, an orally-active pyrazole antithrombotic agent, on arterial thrombosis in rabbits. J Pharmacol Exp Ther 2002; 303: 993-1000.
14. Eriksson BI, Borris LC, Friedman RJ, et al. RECORD1 Study Group. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008; 358: 2765-2775.
15. Lassen MR, Ageno W, Borris LC, et al. RECORD3 Investigators. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008; 358: 2776-2786. (Pubitemid 351930852)
16. Kakkar AK, Brenner B, Dahl OE, et al. RECORD2 Investigators. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 2008; 372: 31-39.
17. Weitz JI. New oral anticoagulants in development. Thromb Haemost 2010; 103: 62-70.
18. Ufer M. Comparative efficacy and safety of the novel oral anticoagulants dabigatran, rivaroxaban and apixaban in preclinical and clinical development. Thromb Haemost 2010; 103: 572-585.
19. Lindhout T, Blezer R, Hemker HC. The anticoagulant mechanism of action of recombinant hirudin (CGP 39393) in plasma. Thromb Haemost 1990; 64: 464-468.
20. Kretz CA, Cuddy KK, Stafford AR, et al. HD1, a thrombin- and prothrombin-binding DNA aptamer, inhibits thrombin generation by attenuating prothrombin activation and thrombin feedback reactions. Thromb Haemost 2010; 103: 83-93.
21. Béguin S, Welzel D, Al Dieri R, et al. Conjectures and refutations on the mode of action of heparins. The limited importance of anti-factor xa activity as a pharmaceutical mechanism and a yardstick for therapy. Haemostasis 1999; 29: 170-178.
22. Fujimoto T, Imaeda Y, Konishi N, et al. Discovery of a tetrahydropyrimidin- 2(1H)-one derivative (TAK-442) as a potent, selective, and orally active factor Xa inhibitor. J Med Chem 2010; 53: 3517-3531.
23. Kawamura M, Konishi N, Hiroe K, et al. Antithrombotic and anticoagulant profiles of TAK-442, a novel factor Xa inhibitor in a rabbit model of venous thrombosis. J Cardiovasc Pharmacol 2010; in press.
24. Hemker HC, Giesen PL, Ramjee M, et al. The thrombogram: monitoring thrombin generation in platelet-rich plasma. Thromb Haemost 2000; 83: 589-591.
25. Ofosu FA, Hirsh J, Esmon CT, et al. Unfractionated heparin inhibits thrombincatalysed amplification reactions of coagulation more efficiently than those catalysed by factor Xa. Biochem J 1989; 257: 143-150.
26. Pieters J, Lindhout T. The limited importance of factor Xa inhibition to the anticoagulant property of heparin in thromboplastin-activated plasma. Blood 1988; 72: 2048-2052.
27. Beguin S, Lindhout T, Hemker HC. The mode of action of heparin in plasma. Thromb Haemost 1988; 60: 457-462.
28. Nagashima H. Studies on the different modes of action of the anticoagulant protease inhibitors DX-9065a and Argatroban. I. Effects on thrombin generation. J Biol Chem 2002; 277: 50439-50444.
29. Majerus PW, Tollfeson DM, Shuman MA. The interaction of platelets with thrombin. In: Platelets in Biology and Pharmacology. North-Holland Publishing 1976; pp. 241-260.
30. Millis DCB, Macfarlene DE. Platelet receptors. In: Platelets in Biology and Pharmacology. North-Holland Publishing 1976; pp. 160-202.
31. Sambrano GR, Weiss EJ, Zheng YW, et al. Role of thrombin signalling in platelets in haemostasis and thrombosis. Nature 2001; 413: 74-78. (Pubitemid 32843490)
32. Covic L, Misra M, Badar J, et al. Pepducin-based intervention of thrombin-receptor signaling and systemic platelet activation. Nat Med 2002; 8: 1161-1165.
33. Lassen MR, Davidson BL, Gallus A, et al. The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement. J Thromb Haemost 2007; 5: 2368-2375.
34. Agnelli G, Haas S, Ginsberg JS, et al. A phase II study of the oral factor Xa inhibitor LY517717 for the prevention of venous thromboembolism after hip or knee replacement. J Thromb Haemost 2007; 5: 746-753. (Pubitemid 46563573)
35. Eriksson BI, Turpie AG, Lassen MR, et al. ONYX study group. A dose escalation study of YM150, an oral direct factor Xa inhibitor, in the prevention of venous thromboembolism in elective primary hip replacement surgery. J Thromb Haemost 2007; 5: 1660-1665.